Abstract：
BACKGROUND: In relation to the different and important roles of the beta2 integrins, we have revisited the expression of polymorphonuclear leukocyte CD18 in several clinical disorders, at baseline and after in vitro activation.
METHODS: we have examined subjects with type 1 diabetes mellitus, vascular atherosclerotic disease, type 2 diabetes mellitus without and with macrovascular complications, chronic renal failure on conservative treatment, essential hypertension, deep venous thrombosis, acute ischemic stroke and subjects with venous leg ulcers.
METHODS: unfractioned leukocyte suspension was prepared according to the Mikita\'s method, while the leukocyte were separated into mononuclear and polymorphonuclear cells with a Ficoll-Hypaque medium. Using specific monoclonal antibody, the CD18 expression was evaluated with cytofluorimetric analysis, using FACScan (Becton Dickinson) be Cellquest software; the activation in vitro with PMA was effected according to modified Yasui and Masuda methods.
RESULTS: in type 1 diabetes mellitus, at baseline CD18 is under expressed in comparison with normal control, and not changes after PMA activation were observed; in subjects with vascular atherosclerotic disease, in type 2 diabetes mellitus CD18 is over expressed at baseline but does not vary after activation; in subjects with chronic renal failure, essential hypertension and in subjects with acute ischemic stroke the CD18 up-regulate at baseline compared to normal control, and it increases further after activation; in subjects with deep venous thrombosis the CD18 expression is not different from control group at baseline, but it increases after activation; finally, in subjects with venous leg ulcers the CD18 is normally expressed at baseline, and it does not change after PMA activation.
CONCLUSIONS: in the different clinical disorders, the trend of this integrin subunit provides some specific information, useful to select the best therapeutic strategy in clinical practice.
METHODS: we have examined subjects with type 1 diabetes mellitus, vascular atherosclerotic disease, type 2 diabetes mellitus without and with macrovascular complications, chronic renal failure on conservative treatment, essential hypertension, deep venous thrombosis, acute ischemic stroke and subjects with venous leg ulcers.
METHODS: unfractioned leukocyte suspension was prepared according to the Mikita\'s method, while the leukocyte were separated into mononuclear and polymorphonuclear cells with a Ficoll-Hypaque medium. Using specific monoclonal antibody, the CD18 expression was evaluated with cytofluorimetric analysis, using FACScan (Becton Dickinson) be Cellquest software; the activation in vitro with PMA was effected according to modified Yasui and Masuda methods.
RESULTS: in type 1 diabetes mellitus, at baseline CD18 is under expressed in comparison with normal control, and not changes after PMA activation were observed; in subjects with vascular atherosclerotic disease, in type 2 diabetes mellitus CD18 is over expressed at baseline but does not vary after activation; in subjects with chronic renal failure, essential hypertension and in subjects with acute ischemic stroke the CD18 up-regulate at baseline compared to normal control, and it increases further after activation; in subjects with deep venous thrombosis the CD18 expression is not different from control group at baseline, but it increases after activation; finally, in subjects with venous leg ulcers the CD18 is normally expressed at baseline, and it does not change after PMA activation.
CONCLUSIONS: in the different clinical disorders, the trend of this integrin subunit provides some specific information, useful to select the best therapeutic strategy in clinical practice.
摘要：
背景：关于β2整合素的不同和重要作用，我们重新审视了多形核白细胞CD18在几种临床疾病中的表达，在基线和体外激活后。
方法：我们检查了1型糖尿病患者，血管动脉粥样硬化疾病，无大血管并发症的2型糖尿病，慢性肾功能衰竭保守治疗，原发性高血压,深静脉血栓形成,急性缺血性中风和下肢静脉性溃疡患者。
方法：根据Mikita方法制备未分级的白细胞悬液，而白细胞用Ficoll-Hypaque培养基分离为单核细胞和多形核细胞。使用特异性单克隆抗体，用细胞荧光分析评估CD18的表达，使用FACScan（BectonDickinson）是Cellquest软件；根据改良的Yasui和Masuda方法进行PMA的体外激活。
结果：在1型糖尿病中，与正常对照相比，基线CD18表达不足，并且在PMA激活后没有观察到变化；在患有血管动脉粥样硬化疾病的受试者中，在2型糖尿病中，CD18在基线时过表达，但在激活后没有变化；在患有慢性肾功能衰竭的受试者中，与正常对照相比，原发性高血压和急性缺血性卒中患者的CD18在基线时上调，激活后进一步增加；在深静脉血栓形成的受试者中，基线时CD18的表达与对照组没有差异，但它在激活后增加；最后，在静脉性腿部溃疡的受试者中，CD18通常在基线表达，PMA激活后不会改变。
结论：在不同的临床疾病中，这个整合素亚基的趋势提供了一些特定的信息，有助于在临床实践中选择最佳的治疗策略。
方法：我们检查了1型糖尿病患者，血管动脉粥样硬化疾病，无大血管并发症的2型糖尿病，慢性肾功能衰竭保守治疗，原发性高血压,深静脉血栓形成,急性缺血性中风和下肢静脉性溃疡患者。
方法：根据Mikita方法制备未分级的白细胞悬液，而白细胞用Ficoll-Hypaque培养基分离为单核细胞和多形核细胞。使用特异性单克隆抗体，用细胞荧光分析评估CD18的表达，使用FACScan（BectonDickinson）是Cellquest软件；根据改良的Yasui和Masuda方法进行PMA的体外激活。
结果：在1型糖尿病中，与正常对照相比，基线CD18表达不足，并且在PMA激活后没有观察到变化；在患有血管动脉粥样硬化疾病的受试者中，在2型糖尿病中，CD18在基线时过表达，但在激活后没有变化；在患有慢性肾功能衰竭的受试者中，与正常对照相比，原发性高血压和急性缺血性卒中患者的CD18在基线时上调，激活后进一步增加；在深静脉血栓形成的受试者中，基线时CD18的表达与对照组没有差异，但它在激活后增加；最后，在静脉性腿部溃疡的受试者中，CD18通常在基线表达，PMA激活后不会改变。
结论：在不同的临床疾病中，这个整合素亚基的趋势提供了一些特定的信息，有助于在临床实践中选择最佳的治疗策略。
